CN1964739A - 抗ctla－4抗体的用途 - Google Patents

抗ctla－4抗体的用途 Download PDF

Info

Publication number
CN1964739A
CN1964739A CNA2005800098282A CN200580009828A CN1964739A CN 1964739 A CN1964739 A CN 1964739A CN A2005800098282 A CNA2005800098282 A CN A2005800098282A CN 200580009828 A CN200580009828 A CN 200580009828A CN 1964739 A CN1964739 A CN 1964739A
Authority
CN
China
Prior art keywords
ser
val
leu
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800098282A
Other languages
English (en)
Chinese (zh)
Inventor
J·戈麦斯-纳瓦罗
D·C·汉森
E·E·米勒
D·A·诺埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1964739A publication Critical patent/CN1964739A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800098282A 2004-03-26 2005-03-14 抗ctla－4抗体的用途 Pending CN1964739A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55680104P 2004-03-26 2004-03-26
US60/556,801 2004-03-26

Publications (1)

Publication Number Publication Date
CN1964739A true CN1964739A (zh) 2007-05-16

Family

ID=35056778

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800098282A Pending CN1964739A (zh) 2004-03-26 2005-03-14 抗ctla－4抗体的用途

Country Status (15)

Country Link
US (1) US20050226875A1 (https=)
EP (1) EP1732600A2 (https=)
JP (1) JP2007530526A (https=)
KR (1) KR100845354B1 (https=)
CN (1) CN1964739A (https=)
AR (1) AR049480A1 (https=)
AU (1) AU2005225227A1 (https=)
BR (1) BRPI0509274A (https=)
CA (1) CA2560919A1 (https=)
IL (1) IL177602A0 (https=)
NO (1) NO20064854L (https=)
RU (1) RU2346702C2 (https=)
TW (2) TW200829271A (https=)
WO (1) WO2005092380A2 (https=)
ZA (1) ZA200607544B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271359A (zh) * 2015-02-13 2018-07-10 索伦托治疗有限公司 结合ctla4的抗体治疗剂
CN115515633A (zh) * 2020-05-12 2022-12-23 百时美施贵宝公司 可活化的抗ctla-4抗体的给药及施用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101691A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
KR20070104673A (ko) * 2005-03-23 2007-10-26 화이자 프로덕츠 인코포레이티드 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
CA2603093A1 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP2365823B1 (en) 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
SMT201700293T1 (it) * 2009-07-20 2017-07-18 Bristol Myers Squibb Co Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
AU2011213609B2 (en) 2010-02-08 2016-11-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
KR20130105652A (ko) * 2010-09-08 2013-09-25 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합
MX357746B (es) 2010-09-08 2018-07-23 Yeda Res And Development Co Ltd Star Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma.
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2013013029A1 (en) 2011-07-19 2013-01-24 The Board Of Trustees Of The University Of Illinois Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
EP3494996B1 (en) 2012-08-23 2026-04-15 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
JP6510518B2 (ja) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
WO2016187356A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
RU2619208C2 (ru) * 2015-10-08 2017-05-12 ДИАМОНДЗЛИТЕ ЛИМИТЕД Тридент Чамберс Способ профилактического лечения при развитии неопластических процессов кожной ткани, таких как меланома, базально-клеточный рак, плоскоклеточный рак
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
RU2021127872A (ru) 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
CA3073984A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
BR112020012364A2 (pt) 2017-12-20 2020-11-24 Harbour Biomed (Shanghai) Co., Ltd anticorpos de ligação a ctla-4 e usos dos mesmos
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
AU2019369340A1 (en) 2018-10-29 2021-05-20 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
CA3145347A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
WO2021066869A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
JP2024523290A (ja) 2021-06-18 2024-06-28 ナミ セラピューティクス， インコーポレイテッド がんの処置およびその方法における使用のための、マスクされたＩ型インターフェロン（ＩＦＮαおよびＩＦＮβ）を含む融合タンパク質組成物
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
EP4727971A1 (en) 2023-06-13 2026-04-22 Adcentrx Therapeutics Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2025034812A2 (en) 2023-08-07 2025-02-13 Tae Life Sciences Llc Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
DK1141028T3 (da) * 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108271359A (zh) * 2015-02-13 2018-07-10 索伦托治疗有限公司 结合ctla4的抗体治疗剂
CN115515633A (zh) * 2020-05-12 2022-12-23 百时美施贵宝公司 可活化的抗ctla-4抗体的给药及施用

Also Published As

Publication number Publication date
RU2006134045A (ru) 2008-03-27
US20050226875A1 (en) 2005-10-13
RU2346702C2 (ru) 2009-02-20
NO20064854L (no) 2006-12-22
ZA200607544B (en) 2008-07-30
KR100845354B1 (ko) 2008-07-09
IL177602A0 (en) 2006-12-10
CA2560919A1 (en) 2005-10-06
JP2007530526A (ja) 2007-11-01
WO2005092380A2 (en) 2005-10-06
WO2005092380A3 (en) 2006-06-15
KR20070007114A (ko) 2007-01-12
AR049480A1 (es) 2006-08-09
BRPI0509274A (pt) 2007-09-04
TW200829271A (en) 2008-07-16
AU2005225227A1 (en) 2005-10-06
TW200602078A (en) 2006-01-16
EP1732600A2 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
KR100531707B1 (ko) 항-ｃｔｌａ-4 항체의 용도
CN1964739A (zh) 抗ctla－4抗体的用途
CN1328571B (zh) 抗ctla-4的人单克隆抗体
US6682736B1 (en) Human monoclonal antibodies to CTLA-4
KR102551269B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
US20040228858A1 (en) Human monoclonal antibodies to CTLA-4
KR101459159B1 (ko) Ｏｘ-2/ｃｄ200에 대한 항체 및 이들의 용도
CA2537876C (en) Antibodies to m-csf
KR101262032B1 (ko) ＭＡｄＣＡＭ에 대한 항체
KR20070067702A (ko) 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
KR20050059263A (ko) 에리트로포이에틴 수용체 결합 항체
CN101027322A (zh) 促红细胞生成素受体结合抗体
KR20070104673A (ko) 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
KR20140076602A (ko) 항-m-csf 항체를 사용한 염증성 장애의 치료 방법
KR20070108259A (ko) Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
HK1103020A (en) Uses of anti-ctla-4 antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103020

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070516

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1103020

Country of ref document: HK